<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097188</url>
  </required_header>
  <id_info>
    <org_study_id>U2787g</org_study_id>
    <nct_id>NCT00097188</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter
      study to evaluate the safety and efficacy of Rituximab in adults with RRMS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the efficacy of rituximab compared with placebo, as measured by MRI scans of the brain for the total number of lesions observed, and to evaluate the safety and tolerability of rituximab in subjects with RRMS.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of rituximab compared with placebo.</measure>
  </secondary_outcome>
  <enrollment type="Actual">104</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability and willingness to provide written informed consent and to comply with the
             schedule of protocol assessments

          -  Age 18--55 years, inclusive

          -  Diagnosis of relapsing MS, as defined by McDonald Criteria 1--4

          -  History of at least one relapse in the subject's medical records during the 1 year
             prior to randomization

          -  EDSS at screening between 0 and 5.0 points, inclusive

          -  For subjects of reproductive potential (males and females), ability and willingness to
             use a reliable means of contraception (e.g., hormonal contraceptive, patch, vaginal
             ring, intrauterine device, physical barrier) during the study, including the safety
             follow-up period, and for up to 1 year after their last dose of study drug, even if
             they have discontinued early from the study

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Incompatibility with MRI

          -  Lack of peripheral venous access

          -  History of severe, allergic, or anaphylactic reactions to humanized or murine
             monoclonal antibodies

          -  Known active bacterial, viral, fungal, or mycobacterial infection, or other infection
             (including atypical mycobacterial disease, but excluding fungal infections of nail
             beds or recurrent herpes infections), or any major episode of infection requiring
             hospitalization or treatment with IV antibiotics within 30 days prior to screening or
             oral antibiotics within 14 days prior to screening

          -  History or presence of recurrent or chronic infection (e.g., hepatitis B or C, HIV, or
             syphilis)

          -  History of cancer, including solid tumors and hematologic malignancies (except fully
             resolved and resected cutaneous basal cell and squamous cell carcinomas of the skin)

          -  History of alcohol or drug abuse within 6 months prior to screening

          -  History of or currently active primary or secondary immunodeficiency

          -  Presence of significant, uncontrolled disease of the cardiovascular, pulmonary, renal,
             hepatic, endocrine, or gastrointestinal systems

          -  Diagnosis of secondary progressive, primary progressive, or progressive relapsing MS

          -  History or presence of vascular disease potentially affecting brain or spinal cord
             (e.g., stroke, transient ischemic attack, severe carotid stenosis, aortic aneurysm,
             intracranial aneurysm, hemorrhage, arteriovenous malformation)

          -  History or presence of myelopathy due to spinal cord compression by disk or vertebral
             disease

          -  History of severe, clinically significant CNS trauma (e.g., cerebral contusion, spinal
             cord compression)

          -  History of intracranial or intraspinal tumor (e.g., meningioma, glioma)

          -  History or presence of potential metabolic cause of encephalopathy or myelopathy
             (e.g., untreated vitamin B12 deficiency, untreated thyroid deficiency)

          -  History or presence of infectious causes of encephalopathy or myelopathy (e.g.,
             syphilis, Lyme disease, human T-cell lymphotropic virus type 1 [HTLV-1], herpes zoster
             myelopathy)

          -  Neuromyelitis optica

          -  History or presence of systemic autoimmune disorders potentially causing progressive
             neurologic disease (e.g., lupus, antiphospholipid antibody syndrome, Sjogrenï¿½s
             syndrome, Behcet disease)

          -  History or presence of sarcoidosis

          -  Relapse within 30 days prior to randomization

          -  Previous treatment with rituximab (MabThera(R)/Rituxan(R))

          -  Treatment with any investigational agent within 90 days of randomization or five
             half-lives of the investigational drug (whichever is longer)

          -  Receipt of a live vaccine within 30 days prior to randomization

          -  Previous treatment with lymphocyte-depleting therapies (e.g., Campath(R), anti-CD4,
             cladribine, total body irradiation, bone marrow transplantation)

          -  Treatment with cyclophosphamide or mitoxantrone within 12 months of randomization

          -  Systemic corticosteroid therapy within 30 days of randomization

          -  Treatment with IFN-Beta; or Copaxone(R) within 60 days of randomization

          -  Treatment with IVIG within 60 days of randomization

          -  Plasmapheresis within 60 days of randomization

          -  Treatment with non-lymphocyte depleting immunosuppressive therapies (e.g.,
             azathioprine, mycophenolate mofetil, cyclosporine) within 90 days prior to
             randomization

          -  Statins or hormone replacement therapy started within 30 days of randomization

          -  Positive pregnancy test

          -  B-cell count &lt;1.1% (reported as percent CD19)

          -  Vitamin B12 below the lower limit of normal with an abnormal methylmalonic acid level

          -  Positive rapid plasma reagin

          -  Serum creatinine &gt;1.4 mg/dL for women or &gt;1.6 mg/dL for men

          -  Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) &gt;2.5 x
             the upper limit of normal

          -  Platelet count &lt;100,000/mL

          -  Hemoglobin &lt;8.5 g/dL

          -  Neutrophils &lt;1.5 x 10^3/mL

          -  Serum IgG levels below 5.65 mg/mL and serum IgM levels below 0.55 mg/mL

          -  Findings on brain MRI scan consistent with clinically significant conditions other
             than MS

          -  Electrocardiogram (ECG) showing significant abnormality that the treating investigator
             determines may jeopardize the subject's health (i.e., acute ischemia, left bundle
             branch, or bifascicular block)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Smith, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Neurological Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Gould Medical Foundation</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of California At Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Institute Of East Bay</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, P.A.</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple Sclerosis Center of Brevard</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Services Of Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center of Vero Beach</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center Of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Neuroscience Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Hospital MS Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Institute For Neurological Disorders</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Billings Clinical Research Division</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meritcare Neuroscience Clinic</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Neuroscience Assoc.,INC</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists of Dallas, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxine Mesinger MS Clinic/ Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family MS Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Neurosurgery Associates of Tacoma, Inc., P.S.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center/Center for Neurological Disorders</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383.</citation>
    <PMID>18272891</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith CH, Waubant E, Langer-Gould A. Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol. 2009 Jun;29(2):104-6. doi: 10.1097/WNO.0b013e3181a63606.</citation>
    <PMID>19491632</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2004</study_first_submitted>
  <study_first_submitted_qc>November 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2004</study_first_posted>
  <last_update_submitted>February 28, 2014</last_update_submitted>
  <last_update_submitted_qc>February 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <keyword>Relapsing remitting multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

